CDKN2A and acute lymphoblastic leukemia: Recently, our group demonstrated that BCP-ALL children with at least one of the genetic alterations including ETV6 (12p13.2) duplication, PAX5 (9p13.2) deletion, and CDKN2A/B (9p21.3) deletion must be classified as those with high-risk ALL, which have worse 3-year disease free survival (3-DFS) (38).